Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606
March 31, 2022 12:00 ET | Quantum Genomics
PARIS, March 31, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Granting of New Patents Protecting QGC606
March 28, 2022 13:35 ET | Quantum Genomics
PARIS, March 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth : ALQGC, OTCQX : QNNTF), a biopharmaceutical company specializing in the development of a new drug class directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Stéphane Cohen Joins Quantum Genomics as Director of Global Operations
March 14, 2022 13:00 ET | Quantum Genomics
PARIS, March 14, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Signs an Exclusive License and Production Agreement with Gulf Pharmaceuticals Industries Julphar
December 06, 2021 02:00 ET | Quantum Genomics
Quantum Genomics will receive up to $20 M in upfront, development and sales milestone payments as well as royalties on future salesJulphar will receive an exclusive license to market firibastat in the...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.
November 25, 2021 12:00 ET | Quantum Genomics
Quantum Genomics will receive up to $11 M in payments and 25% minimum up to 30% royalties on future salesTeva will receive an exclusive license to bring firibastat to its home market, Israel PARIS,...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics and its Partners Reach a New Stage of Development in Asia
October 07, 2021 12:00 ET | Quantum Genomics
The phase III REFRESH study has been approved by the regulatory authorities and ethics committees in South Korea and Taiwan.Pre-marketing activities have been intensified with OEP and DongWha. PARIS,...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
August 27, 2021 04:45 ET | Quantum Genomics
Firibastat is as efficient as the current standard of care (ramipril) in preventing the degradation of the left ventricular ejection fraction (primary endpoint) after myocardial infarction in full...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat
July 08, 2021 02:00 ET | Quantum Genomics
PARIS, July 08, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the...
Logo_Quantum_Genomics-iloveimg-resized.png
Presentation of the Effects of QGC606 in an Experimental Model of Heart Failure at the Annual Congress of the European Society of Cardiology
July 05, 2021 02:00 ET | Quantum Genomics
PARIS, July 05, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), biopharmaceutical company specializing in the development of a new class of drugs acting directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension
May 19, 2021 12:40 ET | Quantum Genomics
PARIS, May 19, 2021 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly...